Quick answer
How do CJC-1295 (No DAC) and sermorelin differ in a laboratory assay? Both are GHRH(1-29) analogs acting on the same pituitary receptor. Sermorelin carries the native sequence; CJC-1295 (No DAC) differs at four positions, including a D-Ala at position 2 that resists dipeptidyl peptidase IV. The difference matters most in serum-containing media and in stocks held for days. Match the two by moles, not milligrams, use the reconstitution calculator for stock volumes and include a native-sequence reference on every plate.
Two peptides, one receptor, different behavior in a dish
Both peptides are 29-residue GHRH(1-29) analogs, and both act on the same target, the pituitary GHRH receptor, a G protein-coupled receptor whose activation raises intracellular cAMP (Mayo and colleagues, 1992). The sermorelin product page describes the unmodified GHRH(1-29) sequence, formula C149H246N44O42S, in 5 mg and 10 mg vials of lyophilized powder. The CJC-1295 (No DAC) product page describes a modified sequence, formula C152H252N44O42, also in 5 mg and 10 mg vials. Both pages state ≥98% HPLC purity and the same storage line: refrigerate at 2–8 °C, −20 °C for long-term, protect from heat, moisture and light.
A general comparison of the two is already in the library as CJC-1295 vs sermorelin. This article takes a narrower question: if you are designing an assay, which ligand should go in which role, and what controls turn a difference between them into a result instead of an artifact?
The sequence differences, read as assay variables
Comparing the two sequences from the product pages residue by residue gives four differences. Each one maps to a variable in an experiment.
| Position | Sermorelin | CJC-1295 (No DAC) | What it changes in an assay |
|---|---|---|---|
| 2 | Ala | D-Ala | Resistance to dipeptidyl peptidase IV; irrelevant in a serum-free buffer, decisive in serum-containing medium |
| 8 | Asn | Gln | Asn8 deamidation was a major degradation route for a GRF analog at pH 7.4 (Friedman and colleagues, 1991); this alters stock stability over days |
| 15 | Gly | Ala | Part of the analog design; no storage or assay-handling consequence is documented here |
| 27 | Met | Substituted (non-sulfur residue) | Methionine can oxidize; the substituted residue cannot, so there is no sulfoxide variant to appear in an aged stock |
Frohman and colleagues (1989) showed that GHRH(1-29)-NH2 is rapidly cleaved between residues 2 and 3 in plasma by a dipeptidyl peptidase IV-type activity, and that a D-amino acid at position 1 or 2 prevents the cleavage. DPP IV is a well-characterized regulator of many peptide hormones (Mentlein, 1999). The consequence for design is simple: in any medium containing serum, plasma or tissue homogenate, the two peptides do not stay at their nominal concentrations for the same length of time.
Matching ligand to experimental question
The table below does not recommend a product; it describes which ligand property each common design asks for.
| Experimental question | What the design needs | Ligand property that matters |
|---|---|---|
| Receptor binding or cAMP response in a clean cell line, serum-free buffer, minutes of exposure | A reference agonist with the native sequence | Native sequence is the baseline; DPP IV is absent, so stability differences are minor |
| Pituitary cell culture in serum-containing medium over hours | A ligand whose concentration holds while cells respond | DPP IV resistance at position 2 matters; the native sequence may be partly cleaved |
| Comparing potency across a series of GHRH analogs | A defined native-sequence control in every plate | Use the unmodified 1-29 sequence as the common reference |
| Studying the effect of N-terminal protection itself | A matched pair differing in the protected position | The pair is informative only if the other substitutions are acknowledged |
| Stock held for weeks at 2–8 °C or −20 °C | Known chemical liabilities | Asn8 and Met27 are the native-sequence weak points; the analog reduces both |
Because the two peptides differ at four positions, not one, a difference in response between them cannot be assigned to a single residue. Researchers who need to isolate the N-terminal change usually add a third, purpose-made analog; a two-peptide comparison supports only a statement about the sequences as supplied.
Controls that make a two-ligand comparison interpretable
- Equimolar, not equal-mass, matching. The two peptides have slightly different molecular masses, so equal milligrams are not equal moles. Convert through the molecular weight; the reconstitution calculator gives stock concentration, and molar matching follows from the formula weight.
- Same diluent, same day. Reconstitute both vials with the same diluent lot at the same time and hold them the same way, so storage history is not a hidden variable.
- Vehicle control. Include a diluent-only control at the highest volume used; a preserved diluent contains benzyl alcohol, which some cell types do not tolerate.
- Time-matched sampling. If the medium contains serum, read both ligands at identical times after addition; a late time point disadvantages the peptide that is cleaved faster.
- Full concentration range. A single concentration cannot show potency. Run a range on a log scale for both ligands and fit curves.
- Receptor-positive and receptor-negative cells. A response in cells that lack the GHRH receptor indicates a non-receptor effect, a handling artifact or contamination.
- Identity and purity records. Confirm from the lot's certificate, where published (see the COA library), what purity and identity data exist for each vial before attributing a difference to the molecules.
Reading the plasma-stability literature correctly
The DPP IV findings come from experiments in plasma and with purified enzyme. They show where native GHRH is cleaved and which substitutions stop it (Frohman and colleagues, 1989). They do not show that a given peptide survives in a particular cell medium, because the DPP IV content of a medium depends on the serum percentage and lot. A researcher who wants to know can simply measure it: spike each peptide into the medium, hold at assay temperature, sample at intervals and quantify by HPLC. The principles of reading such a trace are in understanding HPLC purity, and why mass spectrometry is the method that confirms identity is in HPLC vs mass spectrometry.
Stock preparation and handling for a paired experiment
Both products are lyophilized powders in sealed clear glass vials. Let each cold vial warm to room temperature before opening, add the diluent slowly against the inside wall, swirl and wait; do not shake. The concentration of each stock is vial mass divided by diluent volume, and the same arithmetic applies to both. General step-by-step handling is in how to reconstitute a lyophilized peptide and storage tiers are in storing research peptides.
For a paired experiment, portion each stock into single-use low-binding tubes at once, label compound, lot, concentration and date, and thaw each portion only once. If a protocol includes oxidation-sensitive readouts, remember that methionine-containing peptides can acquire sulfoxide forms during storage (Li and colleagues, 1995); the native sequence has methionine at position 27, while the analog carries a position-27 substitution.
What published work does and does not allow you to say
The literature supports statements about structure, receptor pharmacology and enzymatic stability: that the GHRH receptor couples to cAMP production (Mayo and colleagues, 1992), that native GHRH is cleaved by DPP IV (Frohman and colleagues, 1989; Mentlein, 1999), and that deamidation at Asn8 was a major route of degradation for a related analog (Friedman and colleagues, 1991). It does not supply a validated head-to-head potency ratio for these two exact research-grade materials in your system, and none should be assumed. The ratio you observe is a property of your cells, medium, timing and lots, which is why the controls above matter more than any quoted number. Related reading on neighboring ligands includes sermorelin vs ipamorelin, which compares a GHRH analog with a ghrelin-receptor agonist, and tesamorelin vs CJC-1295.
A short worked layout for a paired plate
One workable layout for a 96-well plate puts each peptide in a log-spaced series of at least six concentrations in triplicate, with a vehicle column, a native-sequence reference column on every plate, and an assay-positive control such as forskolin, which raises cAMP independently of the receptor and so verifies that the cells can respond. Randomize well positions between plates to avoid edge effects, and record the lot, vial number, thaw count and time since reconstitution of every stock used. Analysis fits a four-parameter curve to each series and compares the fitted midpoints with their confidence intervals instead of comparing single wells.
All material discussed is supplied for laboratory research use only; not for human consumption.
Related reading
- CJC-1295 (No DAC) research overview
- Sermorelin research overview
- CJC-1295 DAC vs No DAC research comparison
- Where to buy sermorelin for research
Frequently asked questions
What is the main structural difference between CJC-1295 (No DAC) and sermorelin?
Both are 29-residue GHRH(1-29) analogs. Sermorelin has the native sequence; CJC-1295 (No DAC) differs at positions 2, 8, 15 and 27, according to the sequences on the product pages.
Do the two peptides act on the same receptor?
Yes. Both are GHRH(1-29) analogs, and the target is the pituitary GHRH receptor, a G protein-coupled receptor linked to cAMP production.
Why does serum in the medium matter for this comparison?
Serum contains dipeptidyl peptidase IV-type activity that cleaves native GHRH after residue 2. The D-Ala at position 2 of the analog prevents that cleavage, so concentrations change at different rates.
Can a difference between the two peptides be assigned to one residue?
No. They differ at four positions, so a two-peptide comparison supports statements about the sequences as supplied, not about a single substitution.
Should the peptides be matched by mass or by moles?
By moles. The molecular masses differ slightly, so equal milligrams give unequal molar concentrations. Use the formula weight and the reconstitution calculator.
What is a suitable positive control in a cAMP assay?
Forskolin raises cAMP independently of the receptor and shows that the cells can respond. A native-sequence reference in every plate anchors the ligand comparison.
Do both products have the same storage conditions?
Both product pages state: refrigerate at 2–8 °C, −20 °C for long-term, and protect from heat, moisture and light.
Is there a published potency ratio for the two research materials?
Not for these exact materials in a specific system. Potency depends on cells, medium, timing and lot, so it should be measured in your own assay.
Why mention methionine for sermorelin?
Methionine can oxidize to the sulfoxide during storage. The native sequence has methionine at position 27; the analog carries a position-27 substitution that does not oxidize that way.
Where do I check the batch documentation?
Open the COA library and look for the lot in hand. Record what it shows, or note that none is published yet.
Related reading: Sermorelin Structure: Sequence, Acetate Salt and Synthesis, Sermorelin History: How GHRH (1-29) Was Discovered, Sermorelin In Vitro: Pituitary Cell Assay Models.
References
- Mayo KE. Molecular cloning and expression of a pituitary-specific receptor for growth hormone-releasing hormone. Mol Endocrinol. 1992;6(10):1734-1744. doi:10.1210/mend.6.10.1333056
- Frohman LA, Downs TR, Heimer EP, Felix AM. Dipeptidylpeptidase IV and trypsin-like enzymatic degradation of human growth hormone-releasing hormone in plasma. J Clin Invest. 1989;83(5):1533-1540. doi:10.1172/JCI114049
- Mentlein R. Dipeptidyl-peptidase IV (CD26): role in the inactivation of regulatory peptides. Regul Pept. 1999;85(1):9-24. doi:10.1016/S0167-0115(99)00089-0
- Friedman AR, Ichhpurani AK, Brown DM, et al. Degradation of growth hormone releasing factor analogs in neutral aqueous solution is related to deamidation of asparagine residues. Int J Pept Protein Res. 1991;37(1):14-20. doi:10.1111/j.1399-3011.1991.tb00727.x
- Li S, Schöneich C, Borchardt RT. Chemical instability of protein pharmaceuticals: mechanisms of oxidation and strategies for stabilization. Biotechnol Bioeng. 1995;48(5):490-500. doi:10.1002/bit.260480511
